Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Diabetic Macular Edema (BRDME)
-
Published:2020-08
Issue:8
Volume:4
Page:777-788
-
ISSN:2468-6530
-
Container-title:Ophthalmology Retina
-
language:en
-
Short-container-title:Ophthalmology Retina
Author:
Vader Maartje J.C.,
Schauwvlieghe Ann-Sofie M.E.,
Verbraak Frank D.ORCID,
Dijkman Greetje,
Hooymans Johanna M.M.,
Los Leonoor I.,
Zwinderman Aeilko H.,
Peto TundeORCID,
Hoyng Carel B.,
van Leeuwen RedmerORCID,
Vingerling Johannes R.,
Moll Annette C.ORCID,
van Lith-Verhoeven Janneke J.C.,
Dijkgraaf Marcel G.W.ORCID,
Schlingemann Reinier O.
Funder
Novartis
Bayer
ZonMw
Health Research
Reference31 articles.
1. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema;Wells;N Engl J Med,2015
2. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial;Wells;Ophthalmology,2016
3. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions;Klaassen;Prog Retin Eye Res,2013
4. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies;Duh;JCI Insight,2017
5. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review;Ting;Clin Exp Ophthalmol,2016
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献